Nov 18, 2019
Enrollment and Randomization of 12,463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trial
Oct 07, 2019
BiondVax Receives EUR4M From the European Investment Bank (EIB) in Support of Ongoing Universal Influenza Vaccine Pivotal Phase 3 Trial
Aug 28, 2019
BiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial Results
Jul 16, 2019
BiondVax Announces Rights Offering Fully Subscribed at US$20 Million
Jul 08, 2019
First Participant Enrolled in Second Cohort of BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial
Jun 26, 2019
European Investment Bank VP Attends Signature Event at BiondVax Extending Financing Agreement With BiondVax to EUR24million
Jun 18, 2019
Patent Covering Manufacturing Process of BiondVax's M-001 Universal Flu Vaccine Allowed in USA and Japan
Jun 10, 2019
BiondVax Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial of the M-001 Universal Flu Vaccine and Scale Up of Manufacturing Process
May 30, 2019
BiondVax Announces First Quarter 2019 Financial Results
May 13, 2019
BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at 18th MIXiii-BIOMED Conference
Apr 30, 2019
BiondVax Announces Fourth Quarter and Full Year 2018 Financial Results and Update
Apr 22, 2019
European Investment Bank (EIB) Extends Financing Agreement to EUR24 Million Total in Support of BiondVax's Universal Flu Vaccine Ongoing Pivotal Phase 3 Clinical Trial
Apr 15, 2019
BiondVax Universal Flu Vaccine Patent Application Accepted in Australia
Mar 28, 2019
BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at IVW2019 Conference
Mar 21, 2019
Last Participant out in USA Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate
Nov 26, 2018
BiondVax CEO to Present at 'World Vaccine Congress 2018 San Diego' About BiondVax's Phase 3 Universal Flu Vaccine Candidate
Nov 19, 2018
BiondVax Issues Clarification Regarding Third Quarter 2018 Financial Results
Nov 13, 2018
BiondVax Announces Third Quarter 2018 Financial Results
Oct 24, 2018
BiondVax's Universal Flu Vaccine Phase 3 Clinical Trial Completes First Season's Enrollment of 4,098 Participants
Oct 22, 2018
BiondVax Receives EUR8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial